As part of its Value Blueprints series, IVI’s latest research brief grapples with a question prompted by ICER’s recent assessment of RA therapies: Do conventional value assessments address the questions most relevant to real-world decisions about treatment pathways for chronic diseases? In the brief, the authors discuss how the failure of ICER’s analysis to evaluate [...]
As one of the nine finalists in HealthEconomics.com's inaugural challenge competition to accelerate change in health economics and outcomes research, IVI's Mark Linthicum offered a compelling case for how IVI's Open-Source Value Platform (OSVP) is catalyzing innovation to shake up value assessment. Mark's presentation, "Using Open-Source Models to Improve Value Assessment in the U.S.", outlined [...]
IVI offered comments on ICER's recently released Draft Evidence Report examining the cost-effectiveness of Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis. In addition to commenting on the needs for transparency and the impacts of modeling assumptions on results, IVI's comments raise a broader question about the relevance of the analysis to decision making. IVI writes [...]
At the National Health Council's event, Back to School: Patient Community Training on Value Assessment, IVI executive director Jennifer Bright explains the non-profit organization's mission to make value assessment more relevant to real decision making, how and why patient perspectives must be built into the front end of economic modeling, and how patients and patient [...]
IVI presented two posters at AMCP Nexus 2019, the healthcare conference at the intersection of value and care. In the poster “Understanding Value Through the Patient’s Eyes: Perspectives from Patients with Genetic Mutations in Non-Small Cell Lung Cancer Treatment” researchers show how they examine the perspectives and experiences of patients diagnosed with mNSCLC, and the [...]
Jennifer Bright writes in Benefits Pro that employers who rely on health plans and vendors to advise them on coverage for drugs or other treatments need to ask several key questions to ensure they are getting the most value out of their consultants' recommendations. Read the full article here.
IVI has been selected by the Patient-Centered Outcomes Research Institute (PCORI) for a Eugene Washington PCORI Engagement Award. The $50,000 award will be used to convene a multi-stakeholder forum in February 2020 to review established and emerging approaches for improving value assessment and then identify and prioritize potential areas for research investment and collaborative solutions. [...]
IVI submitted comments to ICER regarding proposed methodological changes for assessments of the value of single or short-term transformative (SST) therapies. IVI emphasized the need for ICER to address the potential use of its findings by decision makers, specifically when short-term budget estimates may discourage investment in therapies with high long-term value, including careful consideration [...]
In a new Value Blueprints research brief, IVI explores the concept of “structural uncertainty,” an important source of uncertainty that is not generally measured or addressed in cost-effectiveness models. In this research brief, we use the IVI-RA model to demonstrate how different structural assumptions lead to varying cost-effectiveness estimates. As our findings make clear, it [...]
At the 2019 ISPOR conference, Jeroen Jansen sat down with AJMC to explain the current state of value assessment and how by putting patients at the frontend of analysis, we can better quantify the value of a treatment. Watch the brief interview here.